Close

AbbVie Completes Acquisition of Landos Biopharma

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

API China, PHARMCHINA & NHNE 2025 Conclude with Global Win

API China, PHARMCHINA & NHNE 2025 Close in Guangzhou...

Under-Eye Wrinkle Treatment: How to Reduce Puffiness and Fine Lines

As we age, the skin around our eyes begins...

Receptor Grade IGF-1 LR3: Expansive Research Potential

Receptor Grade IGF-1 LR3, an engineered analog of Insulin-like...

API China 2025 kicks off with Industry Buzz on Day One

At the China Import and Export Fair Complex in...

AbbVie announced that it has completed its acquisition of Landos Biopharma, Inc  With the completion of the acquisition, Landos is now part of AbbVie.

Landos’ lead investigational asset is NX-13, a first-in-class, oral NLRX1 agonist (a member of the NOD-like receptor family), which is currently in Phase 2 for the treatment of moderate to severe UC (NEXUS study; NCT05785715). NLRX1 regulates immunometabolism and inflammation, and its activation may address inflammatory bowel disease (IBD) pathogenesis. With a dual mechanism of action that is anti-inflammatory and facilitates epithelial repair, NX-13 has the potential to offer a novel approach to the treatment of UC and CD.

“Many people living with IBD are not able to achieve or maintain remission and continue to experience debilitating symptoms,” said Kori Wallace, M.D., Ph.D., vice president, global head of immunology clinical development, AbbVie. “The addition of NX-13 complements our portfolio in immunology and strengthens our collective efforts to transform standard of care. I want to commend the Landos team for their efforts in advancing our shared mission of developing medicines for those who need it most.”

Latest stories

Related stories

API China, PHARMCHINA & NHNE 2025 Conclude with Global Win

API China, PHARMCHINA & NHNE 2025 Close in Guangzhou...

Under-Eye Wrinkle Treatment: How to Reduce Puffiness and Fine Lines

As we age, the skin around our eyes begins...

Receptor Grade IGF-1 LR3: Expansive Research Potential

Receptor Grade IGF-1 LR3, an engineered analog of Insulin-like...

API China 2025 kicks off with Industry Buzz on Day One

At the China Import and Export Fair Complex in...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back